<DOC>
	<DOCNO>NCT02969564</DOCNO>
	<brief_summary>The number metastases patient primary recurrent prostate cancer major prognostic implication . The purpose compare , pilot study , diagnostic performance 18F-NaF-PET/MR respect result scintigraphy 99mTc-MDP-SPECT/CT ( routine exam ) determine presence absence bone lesion prostate cancer patient , five metastasis ( oligo-bone metastatic ) base scintigraphy 99mTc-MDP-SPECT/CT . The gold standard combination clinical follow-up , additional imaging biopsy , indicate multidisciplinary discussion tumor board . The findings whole-body 99mTc-MDP-SPECT/CT , 18F-NaF-PET/MR , combination 2 modality categorize 2 team 2 reader benign probably benign , equivocal , malignant probably malignant compare result follow-up JAFROC ROC analysis .</brief_summary>
	<brief_title>18F-NaF-PET/MR v 99mTc-MDP-SPECT/CT Detect Bone Metastases Prostate Cancer Patients .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Technetium Tc 99m Medronate</mesh_term>
	<criteria>Oligo metastatic patient prostate cancer bone lesion ( five metastasis ) base scintigraphy wholebody SPECT/CT ( stag recurrence ) . Patient must able provide inform consent . Patient â‰¥ 18 year old Patient another active malignancy . Patient &lt; 18 year old Patients contraindication MRI procedure ( metal implant , cardiac pacemaker , old type prosthesis ) Patients severe renal impairment ( MDRD &lt; 30 )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>PET/MRI</keyword>
</DOC>